EcoDrugPlus

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOTSG00005046890
Gene Symbol: P2RY6
3 Cross references
176 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSOTSG00005044460
Gene Symbol: RIPK1L
1 Cross references
192 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSOTSG00005047619
Gene Symbol: RIPK1L
1 Cross references
191 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOTSG00005015728
Gene Symbol: RAMP1
1 Cross references
180 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOTSG00005018949
Gene Symbol: RAMP1
3 Cross references
180 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSOTSG00005014727
Gene Symbol: LOC112237873
3 Cross references
185 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSOTSG00005044015
Gene Symbol: LOC112237873
3 Cross references
184 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSOTSG00005028547
Gene Symbol: RPTOR
1 Cross references
206 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSOTSG00005027393
Gene Symbol: RPTOR
1 Cross references
206 Possible Orthologues:

Renin

Ensembl ID : ENSOTSG00005036679
Gene Symbol: REN
1 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSOTSG00005006825
Gene Symbol: REN
1 Cross references
213 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005041959
Gene Symbol: RET
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).